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Background:  The safety of Patent foramen ovale (PFO) or atrial septal defect (ASD) percutaneous closure in immunosuppressed patients 
or with autoimmune disease is unknown. We attempted to determine if closure is safe in such patients.
methods:  A prospective observational multicenter study was performed in 24 patients who were immunocompromised or had autoimmune 
disease from vasculitis, Human Immunodeficiency Virus (HIV), hepatitis, cancer, or renal transplant and underwent percutaneous PFO or 
ASD closure for cryptogenic stroke (9, 38%), desaturation (5, 21%), migraine (7, 29%), or a combination of these diagnoses (3, 13%). Post 
procedure follow-up included clinic evaluation in 3-6 months or telephone questionnaire up to 8 years (21 ± 28 months).
results:  Of the 24 patients (53 ± 14 years), 19 had a PFO (79%), 5 had an ASD (21%), and 21 underwent closure (88%). No patient 
reported endocarditis, device erosion, exacerbation of migraine, or recurrent stroke. Only 1 patient in the PFO group (4%) experienced a 
transient neurologic deficit after closure. Of the 7 who had migraine prior to closure, 4 (57%) reported resolution of migraines. For patients 
who were unreachable for phone interview, mortality status was verified by the social security death index and revealed 5 deaths which 
were related to non-cardiac conditions in 3 cases (1 of these patients did not receive a device), 1 from metastatic pancreatic cancer, and 1 
was unknown in a 77 year old woman who did not receive a device.
Conclusion:  Percutaneous PFO or ASD closure can be safely performed in patients who are immunocompromised or have autoimmune 
disease and suffer from clinical conditions associated with a septal defect.
